LIZARD KING HERE- I THINK THIS MAY JUST BE THE START OF SOMETHING... EXCEPT FOR THESE LAST TWO BOND AUCTIONS WHICH SUCKED-! S&P 500 (^GSPC)- SNP - SNP Real Time Price. 4,353.61-4.63 (-0.11%) As of 02:00PM EDT. Market open.
VALN Valneva SE WAS $15 NOW $11 NICE LYME VAX PLAY TEAMED WITH PFIZER. $11.42-0.19 (-1.61%)<-- SEE IF THIS TURNS UP HERE IN SUPPORT******1:23 PM 10/11/23
FDA finds no issues in Pfizer/ Valneva Lyme disease vaccine trial SA NewsToday, 2:10 PM Valneva gets new $32M supply contract for the U.S. government SA NewsMon, Sep. 25
Word out of Raymond James says that Take-Two is likely to see “big numbers” ahead as “Grand Theft Auto 6” starts gearing up for release, and actually upgraded the stock just on this. Raymond James hiked its rating from Market Perform to Outperform and added a price target of $170 per share. It calls Take-Two’s likely future “very interesting” and also notes there are reasons to be “incrementally” more optimistic about what’s to come. The biggest sticking point, which is when “Grand Theft Auto 6” will actually emerge, should be settled fairly soon as well. That’s not out of line; after all, one of the biggest events in gaming—the Game Awards—will hit in December. Geoff Keighley’s big show has become what E3 used to be in June: a major touchstone event in which new trailers are debuted before crowds of (mostly online) onlookers. For “Grand Theft Auto 6” to make an appearance at the Game Awards would make sense. It may not happen—just look at what happened back at Gamescom in August—but there’s an opportunity afoot. What is the Stock Price Forecast for Take-Two Interactive? Turning to Wall Street, analysts have a Strong Buy consensus rating on TTWO stock based on 14 Buys and one Hold assigned in the past three months, as indicated by the graphic below. Furthermore, the average TTWO price target of $162.33 per share implies 10.86% upside potential. MEH UPSIDE - T-$170 I DO NOT AGREE I THINK $220.
I DON'T CARE THAT MONEY FLOW AINT GREAT CRSPR IS ONE OF THE BEST IDEAS NOW. As of late last year, CRISPR and Vertex started submitting exa-cel, their blood disorders candidate, to regulatory agencies in the U.S., the U.K., and Europe. The FDA aims to issue a decision on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March. Data have been strong for both indications, so there's reason to be optimistic about exa-cel's future. For example, 94% of patients in the sickle cell trial remained free of pain crises for at least one full year. In the beta thalassemia trial, more than 88% didn't require blood transfusions for at least 12 straight months. NASDAQ: CRSP CRISPR Therapeutics Today's Change (1.39%) $0.61 Current Price $44.45 CRSP Key Data Points Market Cap $3B Day's Range $43.67 - $45.55 Potential for blockbuster revenue Exa-cel could generate $1.7 billion in revenue in 2028, according to Evaluate Pharma, which puts it in blockbuster territory. Of course, CRISPR shares profit with Vertex, and Vertex will take the lion's share -- 60% -- since it also is making a bigger investment in the program's costs. But the potential product still represents a significant amount of revenue for CRISPR. It's also important to note this isn't CRISPR's only near-term opportunity. The company is studying an immuno-oncology candidate in a trial that could support a regulatory submission. If all goes smoothly, this represents another potential product within the next few years. Meanwhile, CRISPR is also generating revenue by licensing its gene-editing technology to others. This spring, Vertex bought access to the platform for use in one of its other programs, one targeting type 1 diabetes.
A LITTLE HEADS UP HERE- I SAW A RATHER MUNDANE UPGRADE OF COHR AND I'M NOT SURE IF I EVEN LISTED IT.. BUT SEEING THE STK ACTING REAL WELL... I NOW SEE THERE WAS AN ADDED REASON FOR UPGRADE-TWO JAPANESE FIRMS $1B INVESTMENT??? AND AI??? Coherent Corp. (NYSE:COHR) was upgraded at investment firm B. Riley amid a $1B investment by two Japanese companies and its artificial intelligence potential. Shares are up 7% on Wednesday morning.